Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VMP followed by Rd versus KRd with or without daratumumab in fit elderly patients with newly diagnosed multiple myeloma
2017-000044-18Phase 3Active
- Sponsor
- Fundación PETHEMA
- Start
- Apr 2018
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of bortezomib, melphalan, prednisone, lenalidomide, dexamethasone and 2 more in multiple myeloma (MM) (3 arms), sponsored by Fundación PETHEMA. Primary endpoint: Immunophenotypic complete response at 18 months. Started Apr 2018; status: active.
02
Drugs
bortezomibmelphalanprednisonelenalidomidedexamethasone
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2017-000044-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-000044-18.